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Abstract. TP53 mutation is a common event in many cancers, 
including thyroid carcinoma. Defective p53 activity promotes 
cancer resistance to therapies and a more malignant pheno-
type, acquiring oncogenic functions. Rescuing the function 
of mutant p53 (mutp53) protein is an attractive anticancer 
therapeutic strategy. Zn(II)-curc is a novel small molecule 
that has been shown to target mutp53 protein in several cancer 
cells, but its effect in thyroid cancer cells remains unclear. 
Here, we investigated whether Zn(II)-curc could affect p53 
in thyroid cancer cells with both p53 mutation (R273H) and 
wild-type p53. Zn(II)-curc induced mutp53H273 downregula-
tion and reactivation of wild-type functions, such as binding 
to canonical target promoters and target gene transactivation. 
This latter effect was similar to that induced by PRIMA-1. 
In addition, Zn(II)-curc triggered p53 target gene expression 
in wild-type p53-carrying cells. In combination treatments, 
Zn(II)-curc enhanced the antitumor activity of chemothera-
peutic drugs, in both mutant and wild-type-carrying cancer 
cells. Taken together, our data indicate that Zn(II)-curc 
promotes the reactivation of p53 in thyroid cancer cells, 
providing in vitro evidence for a potential therapeutic approach 
in thyroid cancers.
Introduction
Thyroid carcinoma is a common malignant tumor of endo-
crine glands and the most common cancer in head and neck; 
it exhibits the full range of malignant behaviors from the 
relatively indolent occult differentiated type to uniformly 
aggressive and lethal anaplastic variety (1). Thyroid tumor 
formation is associated with many genetic and environmental 
causes. In addition, numerous factors are also required to 
promote thyroid cancer progression (2). Although well differ-
entiated thyroid carcinomas are efficiently cured by surgery 
and radioiodine, undifferentiated thyroid carcinomas (10-20% 
of total) are very resistant to chemotherapy (3-6). Therefore, 
novel and more efficacious therapies are urgently needed for 
these tumors.
TP53 is the most commonly mutated gene in human 
cancers, thus, >50% of all human cancer cases carry muta-
tions within the TP53 locus (7). Unlike other oncosuppressors, 
p53 gene always carries a single monoallelic missense muta-
tion that mainly resides in its DNA-binding domain (DBD) 
that abolishes its ability to bind to specific DNA sequences 
recognized by wild-type (wt) p53 (8). Loss of wtp53 activity 
leads to inhibition of its oncosuppressor function promoting 
resistance to chemo- and radio-therapies (9). Mutant p53 
(mutp53) proteins frequently exhibit a dominant-negative 
activity over the wtp53 allele by interacting with wtp53 and 
reducing cellular concentration of functional wtp53 (10). 
Recent studies have shown that mutations of the TP53 gene 
can confer oncogenic functions (gain of function, GOF) that 
are exerted in a variety of ways, ranging from enhanced 
proliferation in culture, increased tumorigenicity in vivo, and 
enhanced resistance to a variety of commonly used anticancer 
drugs (11-13). Indeed, tumors emerging from mutant-p53 
knock-in mice display aggressive and metastatic traits that are 
never detected in tumors developing in a p53-deficient mice 
(14,15). Mutations of p53 are detectable in 15% of malignant 
thyroid tumors and are associated with the progression from 
differentiated to anaplastic carcinoma (16). Thus, p53 muta-
tions have an effect on infiltration, lymphatic metastasis and 
prognosis of thyroid carcinoma (17).
Several efforts are in progress to discover efficient agents, 
such as small molecules, that target mutp53 in cancers, 
including thyroid cancers (18), both to abolish mutp53 function 
or to reactivate the wtp53 counterparts (19). The final aim is 
to restore p53 oncosuppressor functions and improve tumor 
response to therapies. We recently showed that Zn(II) supple-
mentation in several cancer cells carrying mutp53, including 
colon, breast, and glioblastoma, restores a folded conforma-
tion from mutp53 misfolding, rescuing wtp53/DNA-binding 
and transactivation (20-22). The rationale to use Zn(II) comes 
from the fact that p53 protein includes one zinc ion (Zn2+) as 
an important cofactor for the proper protein folding to effi-
ciently bind the DNA of sequence-specific target genes (23). 
Interestingly, mutp53 proteins are prone to the loss of the 
Zn(II) bound to the DNA binding domain (DBD) with the 
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consequence of protein unfolding and aggregation with loss 
of wild-type activity (24), therefore, zinc supplementation has 
been shown to be a useful strategy to target mutp53 proteins 
(25,26).
In this study we asked whether zinc supplementation 
might affect p53 in two different thyroid cancer cell lines, 
one carrying p53-R273H (Arg to His at codon 273) mutation 
(FTC-133) that is one of the p53 mutation responsible of resis-
tance to antitumor drugs (11) and another with wtp53 (WRO). 
We used a novel curcumin-based zinc compound [Zn(II)-curc] 
that we previously showed to reactivate mutp53 proteins (27) 
and to induce mutp53 degradation through autophagy (28). 
Here, we found that Zn(II)-curc reduced mutp53 protein 
levels in FTC-133 cells, reactivating the wtp53 functions with 
increased response to therapies. Of note, Zn(II)-curc also 
inducted wtp53 transcriptional activity in wtp53-carrying cell 
line. These findings suggest that Zn(II)-curc may be a useful 
compound in therapeutic regimens of thyroid cancers, carrying 
both mutant and wtp53, that will be worth further testing for 
translational purpose in clinical practice.
Materials and methods
Cell culture and reagents. Human thyroid FTC-133 cell line 
was obtained from European Collection of Cell Cultures 
(ECACC, Salisbury, UK). It derives from a lymph node metas-
tasis of a follicular thyroid carcinoma and carries p53R273H 
mutation and EGFR overexpression. FTC-133 and WRO 
(wtp53) (ECACC) cancer cell lines were routinely main-
tained in DMEM-Ham's-F12 (Life Technology-Invitrogen), 
supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 100 U/ml penicillin, 100 µg/ml streptomycin (Life 
Technology-Invitrogen), and 2 mmol/l L-glutamine in a 
humidified atmosphere with 5% CO2 and 95% air at 37˚C.
For treatments the following reagents were used: Zn(II)-
curc (29,30) dissolved in DMSO was added to the culture 
medium to a final concentration ranging between 40 and 
120 µM; chemotherapeutic agent adriamycin (ADR) (Sigma), 
dissolved in PBS was added to the culture medium to a final 
concentration ranging between 0.2 and 2 µg/ml and cisplatin 
(Teva Pharma-Italia, Italy) was added to the culture medium 
to a final concentration ranging between 0.5 and 5 µg/ml; 
PRIMA-1 (p53 reactivation and induction of massive apop-
tosis-1) (Sigma) was added to the culture medium to a final 
concentration 10 µM for 24 h. PBS and DMSO solvents were 
used as control.
Viability assay. Exponentially proliferating cells were plated 
at subconfluence in triplicate in 60-mm Petri dishes and 24 h 
later treated with Zn(II)-curc alone or combination with 
chemotherapeutic agents for 24 h. Both floating and adherent 
cells were collected and cell viability was determined by 
trypan blue exclusion by direct counting with a hemocyto-
meter, as reported (31). The percentage of cell viability, as 
blue/total cells, was assayed by scoring 200 cells per well 
three times.
Western blot analysis. Total cell extracts were prepared by 
incubation at 4˚C for 30 min in lysis buffer [50 mmol/l Tris-HCl, 
pH 7.5, 150 mmol/l NaCl, 150 mmol/l KCl, 1 mmol/l dithioth-
reitol, 5 mmol/l EDTA, pH 8.0, 1% Nonidet P-40] plus a mix 
of protease and phosphatase inhibitors (Roche Diagnostic). 
Cell lysates were spun at 15,000 g for 15 min to remove 
debris and collect the supernatant (total cell extracts). Protein 
concentration was then determined using BCA Protein Assay 
kit (Bio-Rad). Equal amount of total cell extracts were resolved 
according to molecular weight on 10-18% SDS-polyacrylamide 
gel electrophoresis. Proteins were transferred to a polyvi-
nylidene difluoride membrane (PVDF, Millipore). Unspecific 
binding sites were blocked by incubating membranes for 1 h in 
0.05% Tween-20 (v/v in TBS) supplemented with 5% non-fat 
powdered milk or bovine serum albumin, followed by over-
night incubation with the following primary antibodies: LC3B 
(Sigma-Aldrich), rabbit polyclonal anti-p53 (FL393), rabbit 
polyclonal anti-p21 and anti-p62 (Santa Cruz Biotechnology, 
Dallas, TX, USA), (p)-Akt (Ser473), tot-Akt (Cell Signaling 
Technologies, Danvers, MA, USA), polyclonal anti-EGFR 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
and purified mouse anti-phospho-histone H2AX (Ser139, 
γH2AX) (Millipore, clone JBW301). Equal lane loading was 
monitored by probing membranes with antibodies specific 
for β-actin (Calbiochem, San Diego, CA, USA) or tubulin 
(Immunological Sciences, Rome, Italy). Primary antibodies 
were detected with appropriate horseradish peroxidase-
labeled secondary antibodies (Bio-Rad, Hercules, CA, USA). 
Enzymatic signals were visualized using chemiluminescence 
(ECL Detection system, GE Healthcare, Milan, Italy).
RNA extraction and semi-quantitative RT-PCR. Cells were 
harvested in TRIzol reagent (Invitrogen) and total RNA was 
isolated following the manufacturer's instructions. The first 
strand cDNA was synthesized from 2 µg of total RNA with 
MuLV reverse transcriptase kit (Applied Biosystems, Foster 
City, CA, USA). Semi-quantitative RT-PCR was performed 
essentially as previously described (20). cDNA was synthesized 
from 2 µg of total RNA with MuLV reverse transcriptase kit 
(Applied Biosystems). Semi-quantitative reverse-transcribed 
(RT)-PCR was carried out by using Hot-Master Taq poly-
merase (Eppendorf S.r.l., Milan, Italy) with 2 µl cDNA reaction 
and gene-specific oligonucleotides under conditions of linear 
amplification. PCR products were resolved on 2% agarose gel 
and visualized with ethidium bromide staining using UV light. 
The 28S mRNA sequence was used as control for efficiency of 
RNA extraction and transcription. Densitometric analysis was 
applied to quantify mRNA levels compared to control gene 
expression.
Chromatin immunoprecipitation (ChIP) assay. ChIP analysis 
was carried out essentially as previously described (20). Briefly, 
cells were crosslinked with 1% formaldehyde for 10 min at room 
temperature and then inactivated by the addition of 125 mM 
glycine. Chromatin extracts containing DNA fragments with 
an average size of 500 bp were incubated overnight at 4˚C 
with milk, shaking using polyclonal anti-p53 antibody (FL393, 
Santa Cruz Biotechnology). Before use, protein G (Pierce) was 
blocked with 1 µg/µl sheared herring sperm DNA and 1 µg/µl 
BSA for 3 h at 4˚C and then incubated with chromatin and 
antibody for 2 h at 4˚C. PCR was performed with Hot-Master 
Taq (Eppendorf) using 2 µl of immunoprecipitated DNA 
and promoter-specific primers spanning p53 binding sites. 
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Immunoprecipitation with non-specific immunoglobulins 
(IgG, Santa Cruz Biotechnology) was performed as negative 
controls. PCR products were resolved on 2% agarose gel and 
visualized by ethidium bromide staining using UV light.
Statistical analysis. Each experiment, unless otherwise speci-
fied, was performed at least three times, and data are presented 
as the mean ± SD. Statistical significance was determined 
using Student's t-test and a P-value of ≤0.05 was considered 
statistically significant.
Results
Zn(II)-curc induces autophagy and mutp53 downregulation 
in FTC-133 cells. We previously reported that Zn(II)-curc 
induces mutp53 degradation through autophagy in breast 
cancer cells (28). As defects in autophagy may be found in 
cancer, we evaluated whether Zn-curc could induce autophagy 
in FTC-133 thyroid cancer cells. We evaluated the expression 
of microtubule-associated protein light chain 3 (LC3) protein 
that, after conversion from LC3-I to its autophagosome 
membrane-associated lipidated form LC3-II, is considered 
a cellular readout of autophagy, and the expression levels of 
p62, a bona fide autophagic substrate (32). As shown in Fig. 1, 
Zn(II)-curc increased LC3-II expression and reduced p62 
levels; parallel to induction of autophagy, Zn(II)-curc triggered 
mutp53 downregulation in FTC-133 cells (Fig. 1). The use 
of chemical inhibitors of autophagic/lysosomal degradation 
cloroquine (CQ) (32) prevented Zn(II)-curc-induced mutp53 
degradation (Fig. 1). These findings indicate that Zn(II)-curc 
induced mutp53 degradation in FTC-133 cells, carrying 
p52R273H mutation, likely through autophagy.
Zn(II)-curc restores wtp53/DNA binding and target gene 
transcription in FTC-133 thyroid cancer cells. We then evalu-
ated whether Zn(II)-curc was promoting reactivation of wtp53 
function in FTC-133 cells. We first performed p53/DNA 
binding by ChIP analyses and found that Zn(II)-curc treat-
ment indeed restored the wtp53 binding to several specific 
target promoters, including Puma, p53AIP1, MDM2, and 
p21, while abolished the p53 binding to the mutant p53 target 
promoter MDR1 (multi-drug resistance 1) (Fig. 2A). As a 
consequence, the expression of the canonical wtp53 target 
genes was evaluated by reverse transcription polymerase chain 
reaction (RT-PCR) analyses. FTC-133 cells were exposed to 
increasing doses of Zn-curc (40, 80 and 120 µM for 24 h) that 
Figure 1. Zn(II)-curc induces autophagy and mutp53 downregulation in 
FTC-133 cells. Subconfluent FTC-133 cells were treated with Zn(II)-curc 
(80 µM) for 16 and 24 h alone or in combination with cloroquine (CQ) 
(25 µM) for 16 h. Equal amount of total cell lysates were subjected to 
immunoblot analysis to detect the indicated proteins. Anti-β-actin was used 
as protein loading control. One representative blot from three independent 
experiments, all revealing similar results, is shown.
Figure 2. Zn(II)-curc restores wtp53/DNA binding and target gene transcription in FTC-133 thyroid cancer cells. (A) FTC-133 cells (4x106) were plated in 
150-mm dish and the day after treated with Zn(II)-curc (80 µM) for 16 h before assayed for chromatin immunoprecipitation (ChIP) analysis with anti-p53 
(FL393) antibody. PCR analyses were performed on the immunoprecipitated DNA samples using primers specific for wtp53 (Puma, p53AIP1, p21, MDM2) 
and mutp53 (MDR1) target gene promoters. A sample representing linear amplification of the total chromatin (input) was included as control. Additional 
controls included immunoprecipitation performed with non-specific immunoglobulins (IgG). (B) Semi-quantitative RT-PCR analyses of p53 target genes 
in FTC-133 cells treated with Zn(II)-curc (40, 80 and 120 µM) for 24 h. 28S was used as a control for efficiency of RNA extraction and transcription. One 
representative experiment, out of two independent experiments with similar results, is shown.
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induced expression of the typical p53 target genes already at 
the lowest dose used, while reduced the expression of mutp53 
target MDR1 expression starting from 80 µM dose (Fig. 2B). 
These findings indicate that Zn(II)-curc produced an imbal-
ance between misfolded/folded p53 proteins in FTC-133 cells 
that favoured wild-type over mutant p53 functions.
Comparison between Zn(II)-curc and PRIMA-1 on p53 
activity. PRIMA-1 is a low molecular weight compound with 
antitumor activity that has been shown to be more effective in 
inducing apoptosis in mutp53 cells than in wtp53 cells (33). 
We then compared the p53 reactivating effect of Zn(II)-curc 
with that of PRIMA-1 in both FTC-133 (mutp53) and WRO 
(wtp53) cells. In vivo transcription of endogenous p53 target 
genes was examined by employing RT-PCR analysis. The 
results show that the induction of wtp53 target genes such as 
Bax, Noxa, Puma and downregulation of the mutp53 target 
gene MDR1 was comparably and efficiently achieved by both 
treatments, that is, Zn(II)-curc and PRIMA-1 (Fig. 3A); of 
note, Zn(II)-curc induced also the wtp53 target, cell cycle-
related p21 gene, unlike PRIMA-1 (Fig. 3A). This latter result 
is in agreement with PRIMA-1 pro-apoptotic specific function 
(33). Interestingly, Zn(II)-curc, differently from PRIMA-1, 
induced p53 target genes in WRO cells, carrying wtp53 
(Fig. 3B), likely due to the DNA intercalating ability of Zn(II)-
curc compound sensing the DNA damage response (29). Thus, 
Zn-curc induced H2AX phosphorylation (γH2AX) (Fig. 3C) 
that is a marker to detect the genotoxic effect of different anti-
cancer agents (34).
Zn(II)-curc modifies prosurvival molecular pathways in 
FTC-133 cells. P53H273 mutation has been shown to increase 
epidermal growth factor receptor (EGFR) levels as well as 
EGFR/PI3K/Akt signaling pathway, facilitating cell prolifera-
tion, tumor growth and migration (35). EGFR overexpression 
is described in several thyroid carcinomas, including follicular 
thyroid carcinomas (36), and recent evidence implicates 
EGFR overexpression in advanced thyroid carcinoma progres-
sion (37). Therefore, we evaluated the effect of Zn(II)-curc on 
EGFR and Akt expression levels in FTC-133 cells. Western 
blot analyses show that the strong expression of EGFR was 
markedly reduced by Zn(II)-curc (Fig. 4A); similarly, Akt 
phosphorylation was noticeably inhibited by Zn(II)-curc 
treatment (Fig. 4B). Moreover, p53 mutants have been shown 
to regulate E-cadherin expression (38). Downregulation of 
the E-cadherin cell-cell adhesion molecule is a key event for 
epithelial to mesenchymal transition (EMT) in tumor progres-
sion and it is associated with the development of invasive 
carcinoma, metastatic dissemination, and poor clinical prog-
nosis (39). We found that Zn(II)-curc induced re-expression 
of E-cadherin mRNA levels in FTC-133 cells, that strongly 
correlated with downregulation of N-cadherin expression, a 
mesenchymal marker (Fig. 4C), as evidenced by densitometric 
analysis (Fig. 4C, lower panel) indicative of a reversion of EMT 
Figure 3. Comparison between Zn(II)-curc and PRIMA-1 on p53 activity. (A) FTC-133 and (B) WRO cells were treated with Zn(II)-curc (80 µM) and 
PRIMA-1 (10 µM ) for 24 h before total mRNAs were reverse transcribed for analysis of p53 target genes, using RT-PCR. 28S was used as a control for effi-
ciency of RNA extraction and transcription. One representative experiment, out of two independent experiments with similar results, is shown. (C) WRO cells 
were treated with Zn(II)-curc (80 µM) for 24 h. Equal amount of total cell extracts were subjected to immunoblot analysis with anti-γH2AX (phopho-Ser139) 
antibody. Anti-β-actin was used as protein loading control.
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Figure 4. Zn(II)-curc modifies prosurvival molecular pathways in FTC-133 cells. (A) Subconfluent FTC-133 cells were treated with Zn(II)-curc (80 µM) for 
16 and 24 h. Equal amount of total cell lysates were subjected to immunoblot analysis to detect p-Akt and total-Akt. Anti-β-actin was used as protein loading 
control. (B) Cells treated as in (A) for 24 h were subjected to immunoblot analysis to detect EGFR expression levels. Anti-β-actin was used as protein loading 
control. One representative experiment, out of two independent experiments with similar results, is shown. (C) FTC-133 cells were treated with Zn(II)-curc 
(80 µM) for 24 h before total mRNAs were reverse transcribed for analysis of E-cadherin and N-cadherin gene expression, using RT-PCR. 28S was used as a 
control for efficiency of RNA extraction and transcription. The lower panel represents densitometric analysis of gene expression, plotted as expression ratio to 
28S. The data represent the mean of two independent experiments ± SD.
Figure 5. Zn(II)-curc increases the cytotoxic effect of drugs. FTC-133 (A) and WRO(B) cells (2x105) were plated at subconfluence in 60-mm Petri dish and 
the day after treated with ADR (0.2 and 2 µg/ml) and cisplatin (cis, 0.5 and 5 µg/ml) alone or in combination with Zn(II)-curc (80 µM) for 24 h. Cell death 
was measured by trypan blue exclusion assay and expressed as percentage ± SD of three independent experiments performed in duplicate. Paired Student's 
t-test was used for statistical analysis of comparison between the values of drugs alone with that of drugs in combination with ZnCl2 treatments. *P<0.01. 
(C) FTC-133 and WRO cells were plated as in (A) and (B) and treated with ADR (0.2 µg/ml) and cisplatin (cis, 0.5 µg/ml) alone or in combination with 
PRIMA-1 (10 µM ) for 24 h. Cell death was measured by trypan blue exclusion assay and expressed as percentage ± SD. *P<0.01.
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phenotype. Altogether, these findings indicate that Zn(II)-curc 
could modify prosurvival pathways and counteract mutp53-
regulated pathways responsible of GOF.
Zn(II)-curc increases the cytotoxic effect of drugs. In order to 
study the biological effect of Zn(II)-curc we treated FTC-133 
and WRO cells with Zn(II)-curc alone or combination with 
cisplatin (cis) or adriamycin (ADR) and assessed viability using 
trypan blue staining. We found that the weak antitumor effect 
achieved by two different doses (0.2 and 2 µg/ml) of ADR 
in FTC-133 cells was significantly increased by Zn(II)-curc 
co-treatment (Fig. 5A). Similarly, cell death induced by both 
low (0.5 µg/ml) or high (5 µg/ml) dose of cisplatin was increased 
by Zn(II)-curc co-treatment, although FTC-133 resulted more 
sensitive to high dose of cisplatin (5 µg/ml) (Fig. 5A); in 
agreement with the activation of wtp53 target genes, seen in 
Fig. 3B, Zn(II)-curc increased the cytotoxic effect of cisplatin 
and ADR also in this wtp53-carrying cell line (Fig. 5B). In 
comparison, PRIMA-1 increased chemosensitivity of mutp53 
FTC133 cells, while did not affect the response to drugs of 
wtp53 WRO cells (Fig. 5C). Altogether, these results show that 
Zn(II)-curc enhanced the cytotoxic effect of chemotherapeutic 
drugs in both mutant and wild-type-carrying cancer cells, 
unlike PRIMA-1 that was effective only in mutp53 cells.
Discussion
In this study we found that Zn(II)-curc, a mutant p53 
reactivator, was able to downregulate mutp53 in FTC-133 
(p53H273) thyroid cancer cells restoring the wtp53 functions 
and improving cancer cell response to antitumor drugs. In 
addition, Zn(II)-curc was also able to activate endogenous 
wtp53 in wtp53 cells WRO.
Several studies have shown that restoration of wild-type 
p53 activity in vitro (40) and in mice (41-43) induces rapid 
tumor regression, demonstrating that reconstitution of p53 is 
indeed sufficient for elimination of tumors even in the presence 
of other tumor-associated genetic alterations (41-43). Over the 
past years several strategies have been approached to develop 
p53-targeted drugs, and in particular to develop small molecule 
compounds that activate wtp53 and restore wtp53 function of 
mutant p53 proteins (44), as abrogation of mutp53 has been 
shown to reduce tumor malignancy (45). Thus, some mutp53 
proteins such as p53H273 have been shown to acquire gain of 
function (GOF) that actively contributes to cancer development 
and progression and chemoresistance (11). At the molecular 
levels GOF effects were shown to be linked to the ability of 
mutp53 to increase the expression of several genes including 
MDR1 (multi-drug resistance gp180 protein). Moreover, 
p53H273 mutation has been shown to increase epidermal 
growth factor receptor (EGFR) levels as well as EGFR/PI3K/
Akt signaling pathway, facilitating cell proliferation and tumor 
growth (35). Here, we found that Zn(II)-curc was able to down-
regulate mutp53 protein levels. In agreement with the loss of 
mutant p53 protein, Zn(II)-curc reduced EGFR expression 
and Akt phosphorylation as well as induced reversion of EMT, 
suggesting modulation of mutp53-dependent gain of function 
pathways. The reversion of EMT by Zn(II)-curc is particularly 
intriguing because EMT induction has been shown to promote 
cancer stem cell (CSC) traits in the thyroid cancer cells, with 
the potential to induce cancer stem cell generation and tumor 
progression in thyroid cancers (46). The effect of Zn(II)-curc 
on mutp53 downregulation depended in part on induction of 
autophagy, as previously reported (28). Autophagy plays a dual 
role during cancer development, progression and treatment, 
mainly depending on the type and stage of the tumor. The 
induction of autophagy by Zn(II)-curc is interesting in light of 
studies showing that, in thyroid cancer, autophagy activation 
increases chemosensitivity, enhances the iodine uptake ability, 
and reverses the dedifferentiation phenotype (47). Parallel to 
mutp53 downregulation, Zn(II)-curc reactivated the wild-type 
p53 functions, likely through the imbalance of misfolded/
folded protein conformation. These molecular changes corre-
lated with improvement, at biological level, of the cytotoxic 
effect of chemotherapeutic drugs, increasing thyroid cancer 
cell death.
The presence of p53 mutations is a late event in thyroid 
cancer progression. The mutations of p53 or increased expres-
sion of p53 protein is associated with the progression from 
differentiated to anaplastic carcinoma and is implicated in 
chemoresistance (17). Recently, some attention has been 
focused on Zinc compounds for p53 reactivation (48). In this 
regard, compounds that can both promote mutp53 degrada-
tion and reactivation of wtp53 functions may have therapeutic 
advantages, as is the case with Zn(II)-curc. To strengthen the 
role of Zn(II)-curc as mutp53 reactivator, the effect of Zn(II)-
curc was compared to that of PRIMA-1, a low molecular 
weight compound that reactivates mutp53 and that has been 
shown to be more effective in inducing apoptosis in mutp53 
cells than in wtp53 cells (33). Such compound has been shown 
to induce cell death in thyroid cancer cells carrying p53 
mutations and particularly p53H273 mutation (18). Of note, 
Zn(II)-curc restored wtp53 activity similarly to PRIMA-1 in 
FTC-133 cells and increased the cytotoxic effect of drugs. In 
addition, Zn(II)-curc was able to activate endogenous wtp53 
in WRO cells, unlike PRIMA-1 that did not have such effect 
on wtp53 protein.
The classic treatment of thyroid cancer is total thyroid-
ectomy, followed by, in some cases, radioiodine treatment. 
Surgically inoperable and radioiodine-refractory differenti-
ated thyroid cancers, poorly differentiated thyroid cancer, 
and anaplastic thyroid cancer are currently the major causes 
of deaths related to thyroid cancer and do not have effective 
treatments (3-6). In this regard, molecular-based management 
strategies for thyroid nodules and thyroid cancer are a novel 
and intense area of development in molecular thyroid-cancer 
medicine (49). In line with this strategy, the present findings, 
although preliminary due to the small number of cell lines 
analyzed, suggest that Zn(II)-curc may be a useful adjuvant in 
the treatment of thyroid cancer cells carrying both both mutant 
and wild-type p53 proteins. Thus, although well differenti-
ated thyroid carcinomas are efficiently cured by surgery and 
radioiodine, undifferentiated thyroid carcinomas (10-20% of 
total) are very resistant to chemotherapy and the restoration 
of chemosensitivity, through p53 reactivation for instance, 
may be an efficient antitumor strategy. The use of Zn(II)-curc 
in clinical practice is strengthen also by our previous studies 
showing other biological effects of zinc supplementation 
such as restoration of immune response (50) and inhibi-
tion of hypoxia-induced molecular pathways (51,52). This is 
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particularly relevant because hypoxia-inducible factor is often 
overexpressed in thyroid cancer contributing to chemoresis-
tance and tumor progression (53). In earlier observations Zn(II) 
has been found to have cytotoxic effect on thyroid cancer cell 
lines (55), although the molecular mechanisms were not fully 
elucidated. Here we propose the use of Zn(II)-curc as p53 (re)
activator in therapeutic regimens of thyroid cancers, carrying 
both mutant and wtp53, that will be worth further testing for 
translational purpose in clinical practice.
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